Amgen Forecasts ‘High Teens’ Growth For Biosimilars

Chairman And CEO Bradway Outlines Expectations For Amgen’s Biosimilars Business

 
• By Dave Wallace

Amgen expects future growth in the “high teens” for biosimilars, chairman and CEO Bob Bradway told the J.P. Morgan Healthcare Conference this week, also setting out his aspirations for the firm’s biosimilars pipeline.

Amgen logo next to syringe
Amgen chairman and CEO Bob Bradway spoke about biosimilars at the J.P. Morgan Healthcare Conference in San Francisco • Source: Shutterstock

More from Biosimilars

More from Products